New copycat cancer drug enters human testing
Disease control
Ongoing
This study is testing a new, similar version of the cancer drug Keytruda (called FYB206) to see if it behaves the same way in the body. It involves patients with stage IIB/IIC or III melanoma who have had their cancer completely removed by surgery. The main goal is to check if th…
Phase: PHASE1 • Sponsor: Formycon AG • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC